What is Design Therapeutics, Inc.'s earnings per share (EPS)?

Design Therapeutics, Inc. (DSGN) reported diluted earnings per share of -$1.22 for fiscal year 2025. This represents a -38.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Design Therapeutics, Inc. (DSGN) Financials

DSGN

FY2025 annual

Revenue $0 YoY not available

Net Income -$69.8M -40.7% YoY

EPS (Diluted) -$1.22 -38.6% YoY

Free Cash Flow -$54.6M -25.6% YoY

Market Cap $729.1M as of Oct 10, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 3.6x on $201.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 3, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DSGN SEC filings page.

Design Therapeutics, Inc. (DSGN) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DSGN FY2025 2026-10-04

The company is funding a cash-consuming research program with a lightly leveraged balance sheet, while annual spending is accelerating.

From FY2024 to FY2025, research spending rose 33.3% while operating cash outflow widened 26.1%; their similar movement indicates the larger loss is primarily tied to development activity rather than a working-capital swing. The pattern describes a business whose accounting losses are closely connected to deliberate cash investment.

The latest net loss was $69.8M against operating cash flow of -$54.4M, with free cash flow at -$54.6M. Cash conversion therefore broadly follows reported profitability, rather than masking the loss through mostly non-cash charges.

At FY2025 year-end, liabilities were only $13.7M against assets of $226.2M. A 17.1x current ratio and 0.1x debt-to-equity indicate financing is primarily equity-based, while the reported liquidity comparison equaled 48.5 months of the latest annual operating outflow—a historical balance-to-outflow measure, not a forecast.

Financial Health Signals

Financial health score not available

Design Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

30.05

Design Therapeutics, Inc. scores 30.05, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($729.1M) relative to total liabilities ($13.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Design Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Design Therapeutics, Inc. reported a net loss of $69.8M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$22.0M

YoY-2.8%

QoQ-12.7%

Design Therapeutics, Inc.'s EBITDA was -$22.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.8% from the same quarter a year earlier. Against the prior quarter it is down 12.7%.

Net Income

-$20.2M

YoY-5.7%

QoQ-14.3%

Design Therapeutics, Inc. reported -$20.2M in net income in Q2 2026. This represents a decrease of 5.7% from the same quarter a year earlier. Against the prior quarter it is down 14.3%.

EPS (Diluted)

-$0.32

YoY+5.9%

QoQ-10.3%

Design Therapeutics, Inc. earned -$0.32 per diluted share (EPS) in Q2 2026. This represents an increase of 5.9% from the same quarter a year earlier. Against the prior quarter it is down 10.3%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$15.5M

YoY-7.0%

QoQ+5.4%

Design Therapeutics, Inc. recorded an outflow of $15.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 7.0% from the same quarter a year earlier. Against the prior quarter it is up 5.4%.

Cash & Debt

$12.9M

YoY-34.5%

QoQ+1.1%

5Y CAGR-48.9%

Design Therapeutics, Inc. held $12.9M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

63M

YoY+9.9%

QoQ+0.2%

5Y CAGR+2.4%

Design Therapeutics, Inc. had 63M shares outstanding in Q2 2026. This represents an increase of 9.9% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-10.0%

YoY-1.0pp

QoQ-1.9pp

Design Therapeutics, Inc.'s ROE was -10.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$16.4M

YoY+4.1%

QoQ+14.0%

Design Therapeutics, Inc. invested $16.4M in research and development in Q2 2026. This represents an increase of 4.1% from the same quarter a year earlier. Against the prior quarter it is up 14.0%.

Capital Expenditures

$21K

YoY-75.9%

5Y CAGR-35.1%

Design Therapeutics, Inc. invested $21K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 75.9% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

DSGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DSGN quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	$0	$0	N/A	N/A	N/A	$226K
R&D Expenses	N/A	$59.1M+33.3%	$44.4M-22.3%	$57.1M+17.4%	$48.6M+96.2%	$24.8M+308.9%	$6.1M
SG&A Expenses	N/A	$20.3M+12.8%	$18.0M-14.6%	$21.1M+11.3%	$19.0M+71.7%	$11.1M+342.8%	$2.5M
Operating Income	N/A	-$79.5M-27.4%	-$62.4M+20.2%	-$78.2M-15.7%	-$67.6M-88.6%	-$35.8M-330.1%	-$8.3M
EBITDA	N/A	-$78.8M-27.6%	-$61.8M+20.4%	-$77.7M-15.6%	-$67.2M-88.2%	-$35.7M-328.9%	-$8.3M
Income Tax	N/A	$0	$0	N/A	N/A	N/A	N/A
Net Income	N/A	-$69.8M-40.7%	-$49.6M+25.8%	-$66.9M-5.6%	-$63.3M-78.2%	-$35.5M-329.1%	-$8.3M
EPS (Basic)	N/A	-$1.22-38.6%	-$0.88+26.1%	-$1.19-4.4%	-$1.14-48.1%	-$0.77	N/A
EPS (Diluted)	-$1.18	-$1.22-38.6%	-$0.88+26.1%	-$1.19-4.4%	-$1.14-48.1%	-$0.77	N/A
Diluted Shares (Avg)	N/A	57M+1.3%	57M+1.1%	56M+0.5%	56M+21.3%	46M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	$0	N/A	N/A	N/A	$0	N/A	N/A
R&D Expenses	$16.4M+4.1%	$14.4M-6.5%	N/A	$14.6M+22.8%	$15.7M+49.7%	$15.4M+56.9%	N/A	$11.9M-10.4%
SG&A Expenses	$5.8M-0.7%	$5.3M+5.7%	N/A	$4.7M+8.1%	$5.8M+28.8%	$5.0M+9.6%	N/A	$4.4M-21.5%
Operating Income	-$22.2M-2.8%	-$19.7M+3.5%	N/A	-$19.3M-18.9%	-$21.6M-43.4%	-$20.4M-41.8%	N/A	-$16.2M+13.7%
EBITDA	-$22.0M-2.8%	-$19.5M+3.5%	N/A	-$19.2M-19.0%	-$21.4M-43.8%	-$20.3M-42.1%	N/A	-$16.1M+13.9%
Net Income	-$20.2M-5.7%	-$17.6M+0.4%	N/A	-$17.0M-30.4%	-$19.1M-61.8%	-$17.7M-59.5%	N/A	-$13.0M+17.4%
EPS (Basic)	-$0.32+5.9%	-$0.29+6.5%	-$0.27-12.5%	-$0.30-30.4%	-$0.34-61.9%	-$0.31-55.0%	-$0.24-14.3%	-$0.23+17.9%
EPS (Diluted)	-$0.32+5.9%	-$0.29+6.5%	-$0.27-12.5%	-$0.30-30.4%	-$0.34-61.9%	-$0.31-55.0%	-$0.24-14.3%	-$0.23+17.9%
Diluted Shares (Avg)	63M+9.9%	61M+8.2%	N/A	57M+0.6%	57M+0.5%	57M+0.5%	N/A	57M+1.1%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

DSGN Balance Sheet

DSGN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$226.2M-10.3%	$252.1M-13.0%	$289.6M-15.1%	$341.1M-12.7%	$390.6M+969.6%	$36.5M
Current Assets	$223.8M-9.8%	$248.0M-12.8%	$284.6M-15.1%	$335.1M-13.1%	$385.4M+963.8%	$36.2M
Cash & Equivalents	$16.9M-25.3%	$22.6M+6.4%	$21.2M-20.0%	$26.5M-91.1%	$298.6M+12450.2%	$2.4M
Short-Term Investments	$203.0M-8.9%	$222.9M-14.5%	$260.6M-14.2%	$303.9M+255.4%	$85.5M+153.6%	$33.7M
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$13.7M+37.1%	$10.0M-16.4%	$12.0M-13.5%	$13.8M+64.1%	$8.4M-82.4%	$47.8M
Current Liabilities	$13.1M+54.3%	$8.5M-12.1%	$9.6M-10.7%	$10.8M+104.0%	$5.3M+126.7%	$2.3M
Non-Current Liabilities	$645K-58.0%	$1.5M-34.3%	$2.3M-23.5%	$3.1M-3.0%	$3.1M-93.1%	$45.5M
Total Equity	$212.5M-12.2%	$242.1M-12.8%	$277.7M-15.2%	$327.3M-14.3%	$382.1M+3477.2%	-$11.3M
Retained Earnings	-$297.0M-30.7%	-$227.2M-27.9%	-$177.6M-60.4%	-$110.8M-133.4%	-$47.5M-298.0%	-$11.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$215.1M-3.5%	$230.4M-3.0%	$226.2M-10.3%	$211.8M-19.1%	$222.9M-17.3%	$237.5M-14.8%	$252.1M-13.0%	$261.6M-12.8%
Current Assets	$212.0M-3.5%	$227.0M-2.8%	$223.8M-9.8%	$209.0M-18.7%	$219.8M-17.0%	$233.6M-14.7%	$248.0M-12.8%	$257.2M-12.7%
Cash & Equivalents	$12.9M-34.5%	$12.8M-6.6%	$16.9M-25.3%	$15.1M-50.3%	$19.7M-56.9%	$13.7M-53.5%	$22.6M+6.4%	$30.3M+8.5%
Short-Term Investments	$194.5M-1.1%	$210.1M-2.8%	$203.0M-8.9%	$190.9M-14.7%	$196.6M-8.7%	$216.0M-10.5%	$222.9M-14.5%	$223.7M-14.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$13.3M+34.7%	$12.4M+29.6%	$13.7M+37.1%	$12.1M+31.3%	$9.8M+18.1%	$9.6M+3.5%	$10.0M-16.4%	$9.2M-38.5%
Current Liabilities	$11.2M+28.5%	$10.2M+23.7%	$13.1M+54.3%	$11.2M+50.3%	$8.7M+36.8%	$8.2M+16.1%	$8.5M-12.1%	$7.4M-40.0%
Non-Current Liabilities	$2.0M+84.3%	$2.2M+66.5%	$645K-58.0%	$877K-49.7%	$1.1M-43.4%	$1.3M-38.4%	$1.5M-34.3%	$1.7M-30.8%
Total Equity	$201.9M-5.2%	$218.1M-4.3%	$212.5M-12.2%	$199.7M-20.9%	$213.0M-18.5%	$227.9M-15.4%	$242.1M-12.8%	$252.5M-11.4%
Retained Earnings	-$334.8M-26.8%	-$314.6M-28.5%	-$297.0M-30.7%	-$281.0M-31.6%	-$264.0M-31.7%	-$244.9M-29.8%	-$227.2M-27.9%	-$213.6M-28.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

DSGN Cash Flow Statement

DSGN quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$55.1M	-$54.4M-26.1%	-$43.1M+26.4%	-$58.6M-14.1%	-$51.3M-74.7%	-$29.4M-238.9%	-$8.7M
Depreciation & Amortization	N/A	$622K+4.4%	$596K+11.0%	$537K+32.3%	$406K+214.7%	$129K+2480.0%	$5K
Stock-Based Compensation	N/A	$14.5M+11.3%	$13.1M-0.1%	$13.1M+19.8%	$10.9M+133.0%	$4.7M+942.0%	$450K
Capital Expenditures	$55K	$193K-43.2%	$340K+32.8%	$256K-72.1%	$918K-40.3%	$1.5M+1923.7%	$76K
Free Cash Flow	-$55.1M	-$54.6M-25.6%	-$43.4M+26.1%	-$58.8M-12.6%	-$52.2M-69.0%	-$30.9M-253.5%	-$8.7M
Investing Cash Flow	$2.4M	$22.9M-47.9%	$44.0M-16.3%	$52.5M+123.8%	-$221.0M-312.0%	-$53.6M-59.8%	-$33.6M
Financing Cash Flow	$45.9M	$25.7M+4917.2%	$513K-29.1%	$724K+208.1%	$235K-99.9%	$379.2M+751.5%	$44.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$15.5M-7.5%	-$16.4M+2.1%	-$12.0M-21.4%	-$11.2M-16.9%	-$14.4M-28.3%	-$16.8M-35.0%	-$9.9M+23.0%	-$9.5M+34.3%
Depreciation & Amortization	$151K-0.7%	$157K-1.3%	$156K+4.7%	$155K+1.3%	$152K+0.7%	$159K+11.2%	$149K+8.0%	$153K+11.7%
Stock-Based Compensation	$3.9M-3.0%	$3.9M+10.9%	N/A	$3.6M+15.1%	$4.0M+20.8%	$3.5M+11.1%	N/A	$3.1M-3.1%
Capital Expenditures	$21K-75.9%	$0-100.0%	$34K	$0-100.0%	$87K-46.0%	$72K-63.1%	$0-100.0%	-$16K-69.8%
Free Cash Flow	-$15.5M-7.0%	-$16.4M+2.6%	-$12.0M-21.7%	-$11.2M-16.7%	-$14.5M-27.2%	-$16.9M-33.5%	-$9.9M+23.1%	-$9.6M+34.4%
Investing Cash Flow	$15.1M-25.2%	-$7.6M-196.4%	-$11.6M-732.3%	$6.5M+211.7%	$20.1M-26.4%	$7.9M-61.8%	$1.8M-67.0%	-$5.8M-138.2%
Financing Cash Flow	$605K+67.6%	$19.9M+86569.6%	$25.3M+9526.2%	$37K+3600.0%	$361K+57.6%	$23K+15.0%	$263K-47.5%	$1K-92.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

DSGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DSGN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	-3685.8%
Net Margin	N/A	N/A	N/A	N/A	N/A	-3663.7%
Return on Equity	-32.8%-12.4pp	-20.5%+3.6pp	-24.1%-4.7pp	-19.3%-10.0pp	-9.3%	N/A
Return on Assets	-30.9%-11.2pp	-19.7%+3.4pp	-23.1%-4.5pp	-18.6%-9.5pp	-9.1%+13.6pp	-22.7%
Current Ratio	17.14-12.2x	29.31-0.3x	29.58-1.5x	31.10-41.9x	72.96+57.4x	15.55
Debt-to-Equity	0.060.0x	0.040.0x	0.040.0x	0.040.0x	0.02	N/A
Asset Turnover	0.000.0x	0.00	N/A	N/A	N/A	0.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	-3869.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-10.0%-1.0pp	-8.1%-0.3pp	N/A	-8.5%-3.3pp	-9.0%-4.5pp	-7.8%-3.7pp	N/A	-5.2%+0.4pp
Return on Assets	-9.4%-0.8pp	-7.6%-0.2pp	N/A	-8.0%-3.0pp	-8.6%-4.2pp	-7.5%-3.5pp	N/A	-5.0%+0.3pp
Current Ratio	18.86-6.3x	22.28-6.1x	17.14-12.2x	18.71-15.9x	25.13-16.3x	28.37-10.2x	29.31-0.3x	34.61+10.8x
Debt-to-Equity	0.070.0x	0.060.0x	0.060.0x	0.060.0x	0.050.0x	0.040.0x	0.040.0x	0.040.0x
Asset Turnover	N/A	0.000.0x	N/A	N/A	N/A	0.00	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Design Therapeutics, Inc. DSGN	FY2025	$0	-$69.8M	N/A	$729.1M	—
Larimar Therapeutics, Inc. LRMR	FY2025	N/A	-$165.7M	N/A	$277.4M	—
4D Molecular Therapeutics, Inc. FDMT	FY2025	$85.2M	-$140.1M	N/A	$736.4M	72/100
Rocket Pharmaceuticals, Inc. RCKT	FY2025	$0	-$223.1M	N/A	$281.0M	—
Assembly Biosciences, Inc ASMB	FY2025	$72.3M	-$6.1M	-8.5%	$479.1M	61/100
Tectonic Therapeutic, Inc. TECX	FY2025	N/A	N/A	N/A	$456.1M	—

Where Design Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Design Therapeutics, Inc.'s annual revenue?

Design Therapeutics, Inc. (DSGN) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Design Therapeutics, Inc. profitable?

No, Design Therapeutics, Inc. (DSGN) reported a net income of -$69.8M in fiscal year 2025.

What is Design Therapeutics, Inc.'s EBITDA?

Design Therapeutics, Inc. (DSGN) had EBITDA of -$78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Design Therapeutics, Inc.'s return on equity (ROE)?

Design Therapeutics, Inc. (DSGN) has a return on equity of -32.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Design Therapeutics, Inc.'s free cash flow?

Design Therapeutics, Inc. (DSGN) recorded an outflow of $54.6M in free cash flow during fiscal year 2025. This represents a -25.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Design Therapeutics, Inc.'s operating cash flow?

Design Therapeutics, Inc. (DSGN) recorded an outflow of $54.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Design Therapeutics, Inc.'s total assets?

Design Therapeutics, Inc. (DSGN) had $226.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Design Therapeutics, Inc.'s capital expenditures?

Design Therapeutics, Inc. (DSGN) invested $193K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Design Therapeutics, Inc. spend on research and development?

Design Therapeutics, Inc. (DSGN) invested $59.1M in research and development during fiscal year 2025.

How many shares does Design Therapeutics, Inc. have outstanding?

Design Therapeutics, Inc. (DSGN) had 62M shares outstanding as of fiscal year 2025.

What is Design Therapeutics, Inc.'s current ratio?

Design Therapeutics, Inc. (DSGN) had a current ratio of 17.14 as of fiscal year 2025, which is generally considered healthy.

What is Design Therapeutics, Inc.'s debt-to-equity ratio?

Design Therapeutics, Inc. (DSGN) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Design Therapeutics, Inc.'s return on assets (ROA)?

Design Therapeutics, Inc. (DSGN) had a return on assets of -30.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Design Therapeutics, Inc.'s P/E ratio?

Design Therapeutics, Inc. (DSGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $729.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Design Therapeutics, Inc.'s price-to-sales ratio?

Design Therapeutics, Inc. (DSGN) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $729.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Design Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Design Therapeutics, Inc. (DSGN) held $219.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $54.4M over that year. Dividing the one by the other, the reported balance equals about 49 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Design Therapeutics, Inc.'s Altman Z-Score?

Design Therapeutics, Inc. (DSGN) has an Altman Z-Score of 30.05, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Design Therapeutics, Inc.'s Piotroski F-Score?

Design Therapeutics, Inc. (DSGN) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Design Therapeutics, Inc.'s earnings high quality?

Design Therapeutics, Inc. (DSGN) reported a net loss of $69.8M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.